Updated September 26, 2026.
Rapamycin, also called sirolimus, is being studied in aging research. It should not be described as a proven way to extend human life or prevent age-related disease. This update separates clinical research from established prescribing uses.
Why researchers study rapamycin
Rapamycin affects the mTOR pathway, which is involved in cell growth and metabolism. Animal findings have motivated human studies. A biological mechanism, however, does not by itself demonstrate that a treatment helps people live longer or remain independent.
What the PEARL trial found
The 2025 PEARL trial studied intermittent rapamycin over 48 weeks. Its primary measure, visceral adiposity, did not improve significantly. Some secondary and subgroup measures improved, and adverse-event rates were similar between groups. The study did not establish longer human lifespan or prevention of dementia, cancer, or cardiovascular disease.
These findings support further investigation, not a universal longevity prescription. The authors disclosed employment and shareholding in AgelessRx; independent replication and longer follow-up remain important when interpreting the results.
Approved use and safety are separate questions
The sirolimus prescribing information describes specific medical indications, including prevention of kidney-transplant rejection. It does not establish an approved anti-aging indication.
Important risks include increased susceptibility to infection, impaired wound healing, lipid changes, and drug interactions. Risks observed in transplant treatment cannot simply be assigned unchanged to every lower-dose regimen, but lower dosing also should not be assumed to eliminate them.
What changed in this article
We removed broad statements about boosting immunity, preventing Alzheimer’s disease or cardiovascular conditions, and assuring cellular longevity. We also removed the suggestion that side effects are generally minor. Animal lifespan percentages are not presented as expected human outcomes.
Questions for a clinical discussion
- What outcome is being sought, and has it been demonstrated in people like me?
- Is the proposed use off-label or part of a clinical trial?
- What interactions, medical conditions, or planned procedures affect risk?
- What monitoring and stopping criteria would be needed?
Schedule a consultation to discuss prevention goals and evidence-based options. This article does not recommend a rapamycin dose or anti-aging regimen.
